Marrone Bio Innovations FCF Margin
Delisted
The Free Cash Flow Margin of Marrone Bio Innovations (MBII) as of Jul 25, 2026 is -24.95 %. In the previous year, Free Cash Flow Margin was -16,518.00 % — a change of -99.85% (higher).
Get this data via API
Financial Data API
FCF Margin
-24.95 %
YoY
-99.85%
Last updated:
Free Cash Flow Margin of Marrone Bio Innovations is 2026 -24.95 % . Free Cash Flow Margin of Marrone Bio Innovations was 2025 -16,518.00 % . It decreases by -99.85% higher compared to the previous year.
Access this data via the Eulerpool API
Marrone Bio Innovations Stock analysis
What does Marrone Bio Innovations do? Marrone Bio Innovations Inc is an American company that has been operating in the field of biological pest control since 2006. It was founded by chemist Dr. Pamela Marrone and is headquartered in Davis, California. The company's business model is based on developing safe and effective biological pest control products made from natural ingredients. The aim is to minimize the environmental impact of agriculture. The company is divided into different divisions, including biological plant protection, biological nitrogen fixation, biological weed control, and other products. Some of the well-known products include Regalia®, Venerate®, and Majestene®. Marrone Bio Innovations has gained significance in recent years and is now one of the leading companies in the field of biological pest control. The company works closely with farmers, research institutions, and regulatory authorities to develop and introduce new products, always prioritizing safety and environmental compatibility. Marrone Bio Innovations is one of the most popular companies on Eulerpool.
Frequently Asked Questions about Marrone Bio Innovations stock
Free Cash Flow Margin of Marrone Bio Innovations is -24.95 % in 2026.
Access this data via the Eulerpool API
Margins — Marrone Bio Innovations
All Key Metrics — Marrone Bio Innovations
Valuation
Income Statement
Margins
Balance Sheet
- Total Assets
- Current Assets
- Cash & Equivalents
- Receivables
- Inventory
- Property, Plant & Equipment
- Goodwill
- Intangible Assets
- Equity
- Liabilities
- Debt
- Current Liabilities
- Long-term Debt
- Short-term Debt
- Retained Earnings
- Book Value per Share
- Tangible Book Value per Share
- Working Capital
- Investments
- Accounts Payable
- Non-Current Assets
- Short-Term Investments
- Long-Term Investments
- Net Debt
- Treasury Stock
- Minority Interest
- Deferred Tax Liabilities
- Net Tangible Assets
- Goodwill/Assets
- Intangibles/Assets
Cash Flow
- Operating Cash Flow
- Capital Expenditures
- Free Cash Flow
- FCF per Share
- Dividends Paid
- Share Buybacks
- Investing Cash Flow
- Financing Cash Flow
- CapEx / Revenue
- Cash Flow per Share
- Stock-Based Compensation
- Change in Working Capital
- Acquisitions (Net)
- Net Change in Cash
- CapEx/OCF
- FCF/Net Income
- FCF Conversion
- Cash Conversion
- Total Shareholder Payout
- CapEx/D&A
Profitability
- ROE
- ROA
- ROCE
- ROIC
- Asset Turnover
- Inventory Turnover
- Receivables Turnover
- Days Sales Outstanding
- Days Inventory Outstanding
- Days Payable Outstanding
- Cash Conversion Cycle
- CROIC
- Gross Profit/Assets
- Fixed Asset Turnover
- Equity Turnover
- Working Capital Turnover
- Payables Turnover
- Capital Intensity
- Receivables/Revenue
- Inventory/Revenue
- EBIT/Assets
Leverage
Growth
- Revenue Growth
- Revenue CAGR 3Y
- Revenue CAGR 5Y
- Revenue CAGR 10Y
- Earnings Growth
- EPS Growth
- EBIT Growth
- EBIT CAGR 3Y
- EBIT CAGR 5Y
- EBIT CAGR 10Y
- Dividend Growth
- FCF Growth
- Book Value Growth
- Earnings CAGR 3Y
- Earnings CAGR 5Y
- Earnings CAGR 10Y
- EPS CAGR 3Y
- EPS CAGR 5Y
- EBITDA Growth YoY
- EBITDA CAGR 3Y
- EBITDA CAGR 5Y
- Gross Profit Growth
- OCF Growth YoY
- Employee Growth
- Dividend CAGR 3Y
- Dividend CAGR 5Y
- Dividend CAGR 10Y
- Asset Growth
- Equity Growth
- Debt Growth
- CapEx Growth
- FCF CAGR 3Y
- FCF CAGR 5Y
- Market Cap Growth
- Share Count Growth